Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Headaches are an uncommon but reported mild side effect in a small subset of users, particularly when starting supplementation or at higher doses
SURMOUNT-1 reported up to 22.5% mean body-weight reduction at the highest studied dose over 72 weeks
When evaluating the number needed to treat to lower risk of cardiovascular events among patients with diabetes, a substantially lower number needed to treat over 6 years compared with 1 year was observed, 32 suggesting that the cardiovascular benefits of GLP-1 RAs in patients with diabetes become more pronounced with long-term use
Some medications can cause this potentially life-threatening condition, but it has also been linked to other treatments like glutathione injections
Handling and Storage Recommendations Store unopened vials at 28 C If frozen storage is used, maintain at 20 C Protect from direct light exposure Avoid moisture contamination during handling Allow vial to equilibrate before reconstitution to reduce condensation After reconstitution, store at 28 C and minimize freezethaw cycles Research Use Only Notice This product is intended for laboratory research use only and is not approved for human or veterinary use